These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 19318041)

  • 1. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease.
    Schiffmann R
    Handb Clin Neurol; 2015; 132():231-48. PubMed ID: 26564084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry Disease: A Disorder of Childhood Onset.
    Schiffmann R; Ries M
    Pediatr Neurol; 2016 Nov; 64():10-20. PubMed ID: 27555236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
    Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
    Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
    Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fabry disease in Italy: first epidemiologic and collaborative study].
    Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
    Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-galactosidase A in vascular disease.
    Bodary PF; Shayman JA; Eitzman DT
    Trends Cardiovasc Med; 2007 May; 17(4):129-33. PubMed ID: 17482095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
    Germain DP; Poenaru L
    Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
    Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cerebral vasculopathy of Fabry disease.
    Moore DF; Kaneski CR; Askari H; Schiffmann R
    J Neurol Sci; 2007 Jun; 257(1-2):258-63. PubMed ID: 17362993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Fabry disease.
    Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
    Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
    Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
    Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.